Recombinant Human CEACAM-19 Fc Chimera Protein, CF Summary
|Human CEACAM-19 |
Accession # Q7Z692-1
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 500 μg/mL in PBS.
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Immobilized Recombinant Human CEACAM-19 (Catalog # 9397-CM) enhances L Cells mouse fibroblasts adhesion. The ED50 for this effect is 0.4-2.4 μg/mL.
Carcinoembryonic antigen-related cell adhesion molecule-19 (CEACAM-19), also known as CEA-like gene 1 (CEAL1), is a member of the CEACAM subfamily of glycoproteins in the immunoglobulin (Ig) superfamily. Mature human CEACAM-19 consists of a 125 amino acid (aa) extracellular domain, a 21 aa helical transmembrane domain, and a 122 aa cytoplasmic domain (1,2). The extracellular domain contains an Ig-like domain as well as a glycosylation site, while the cytoplasmic domain is predicted to contain at least one immunoreceptor tyrosine-based activation motif (ITAM) (3,4). The extracellular domain of human CEACAM-19 shows 71%, 72%, and 78% aa identity to mouse, rat, and bovine CEACAM-19. The CEACAM family of proteins are involved in numerous intercellular-adhesion and intracellular signaling processes including cell adhesion, cell growth, recognition and differentiation, angiogenesis, and apoptosis (5,6). CEACAM-19 expression has been identified in a wide range of tissues including prostate, uterus, fetal brain, mammary and adrenal glands, skeletal muscle, small intestine, and kidney (1). Human CEACAM-19 has been found to be overexpressed in BT-474, BT20, and T47D breast cancer cell lines as well as LNCaP prostate cancer cells, suggesting a role in tumor progression and metastasis (1,3, 7). The overexpression in breast cancer patients is associated with poor prognosis (7).
- Schorilas, A. et al. (2003) Gene 310:79.
- Estiar, M. et al. (2016) Clin Exp Med doi:10.1007/s10238-016-0442-1.
- Beauchemin, N. and Arabzadeh, A. (2013) Cancer Metastasis Rev 32 (3-4):643.
- Kuespert, K. et al. (2006) Curr Opin Cell Biol 18:565.
- Obrink, B. (1997) Curr Opin Cell Biol 9:616.
- Horst, AK. and Wagener, C. (2004) Handb Exp Pharmacol 283.
- Michaelidou, K. et al. (2013) Int J Oncol 42:1770.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human CEACAM-19 Fc Chimera Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human CEACAM-19 Fc Chimera Protein, CF and earn rewards!
Have you used Recombinant Human CEACAM-19 Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image